Mira Pharmaceuticals (MIRA) Receivables - Net (2023 - 2024)
Mira Pharmaceuticals (MIRA) posted Receivables - Net of $5000.0 for Q4 2024, little changed sequentially from $5000.0 in Q4 2023, and little changed YoY from $5000.0 in Q1 2024.
Mira Pharmaceuticals (MIRA) Receivables - Net (2023 - 2024) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of Receivables - Net data on file, last reported at $5000.0 in Q4 2024.
- Quarterly Receivables - Net changed 0.0% year-over-year to $5000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $5000.0, changed 0.0% from the prior year.
- Receivables - Net was little changed at $5000.0 in Q4 2024 per MIRA's latest filing, from $5000.0 in the prior quarter.
- The five-year high for Receivables - Net was $5000.0 in Q4 2023, with the low at $5000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Dec 31, 2023 | 5,000.00 |